Drug Trial Radar · NCT03823807
A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC
Last checked: Nov 19, 2026Latest source record: Feb 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
300
Planned (sponsor's estimate)
Start
Mar 2019
Primary completion
Dec 2020
Study completion Mar 2021
Sponsor
- Lead sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of SH-1028 with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene.
Conditions
- Non-Small Cell Lung Cancer
Interventions
SH-1028Drug
Oral,100mg or 200mg ,QD, fasted
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Every 2 cycles (21 days for 1 cycle) until end of treatment, an average of 1 year.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.